Benjamin Saylor | Authors


Long-Term Responders of Apalutamide Identified With Molecular Signature in nmCRPC

February 13, 2021

A molecular signature has been identified that can characterize long-term responders from treatment with apalutamide and androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer, according to findings, presented at the 2021 Genitourinary Cancers Symposium.

Apalutamide With ADT Maintains OS Benefit in mCSPC

February 13, 2021

Apalutamide in combination with androgen deprivation therapy led to a reduction in the risk of death of 35% in comparison with ADT alone for patients with metastatic castration-sensitive prostate cancer in a final analysis of the phase 3 TITAN trial.

In ARAMIS Trial, Crossover Has Minimal Impact on Darolutamide OS Benefit

February 12, 2021

In patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), crossover from placebo to darolutamide (Nubeqa) appeared have minimal impact on the overall survival (OS) benefit observed with the androgen receptor inhibitor in the pivotal phase 3 ARAMIS trial.

Durvalumab With or Without Tremelimumab Fails to Meet OS Endpoints in Urothelial Cancer

September 19, 2020

The co-primary end points of overall survival in patients with metastatic urothelial cancer were not met in the phase 3 DANUBE trial of durvalumab in combination with tremelimumab and durvalumab monotherapy, according to results presented at the 2020 ESMO Virtual Congress.